Hualan Biological Engineering Inc. (SHE:002007)

Market Cap	29.44B
Revenue (ttm)	4.46B
Net Income (ttm)	1.14B
Shares Out	1.83B
EPS (ttm)	0.62
PE Ratio	25.86
Forward PE	21.48
Dividend	0.20 (1.24%)
Ex-Dividend Date	Jun 14, 2024

Volume	6,496,564
Average Volume	8,359,538
Open	16.10
Previous Close	16.15
Day's Range	16.08 - 16.22
52-Week Range	13.72 - 19.70
Beta	0.65
RSI	47.51
Earnings Date	Aug 29, 2025

About SHE:002007

Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes blood products, vaccines, and recombinant proteins in China and internationally. The company offers blood products under the Hualan brand comprising human albumin, intravenous human immunoglobulin, human immunoglobulin, tetanus human immunoglobulin, hepatitis B human immunoglobulin, rabies immunoglobulin, human prothrombin complex, human coagulation factor VIII, human fibrinogen, freeze-dried human fibrin glue for surgery, and hum...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 4,012
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002007

Financial Performance

In 2024, SHE:002007's revenue was 4.38 billion, a decrease of -18.02% compared to the previous year's 5.34 billion. Earnings were 1.09 billion, a decrease of -26.57%.